On May 6, 2024, Cellectis S.A., closed the transaction. As the result of the transaction, AstraZeneca PLC, now owns approximately 44% of the share capital and 30% of the voting rights of the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11,930 GBX | -0.81% | -3.48% | +12.55% |
09:56am | AstraZeneca drug lowers cholesterol in phase 1 trial | AN |
09:46am | Cellectis: operations financed until 2026 | CF |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
11,930 GBX | -0.81% | -3.48% | 24TCr | ||
2.395 EUR | -2.24% | -7.88% | 27Cr | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.55% | 24TCr | |
+38.69% | 73TCr | |
+30.57% | 59TCr | |
-7.71% | 35TCr | |
+15.47% | 32TCr | |
-0.33% | 27TCr | |
+6.65% | 20TCr | |
-6.09% | 20TCr | |
-3.00% | 16TCr | |
-2.28% | 12TCr |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Cellectis S.A. announced that it has received $140 million in funding from AstraZeneca PLC